Aktienanalyse zu Kairos Pharma Ltd (KAPA)KAPAKairos Pharma Ltd

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Its therapy includes antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its portfolio consists of seven drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301 and 401 and therapeutic agents ENV 105 and 205. KROS 101 is a small molecule that targets the glucocorticoid-induced tumor necrosis factor ligand-related (GITR) ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers. KROS 201 is a T cell therapy activated by dendritic cells to treat glioblastoma, a deadly and common brain cancer. ENV 105 drug seeks to address unmet medical needs in large markets of prostate and lung cancers. It operates in the Healthcare sector.

Kairos Pharma Ltd (KAPA) is not a good buy right now. The stock has seen a staggering year-to-date decline of 67.49% and a one-year change of 83.18%. Additionally, the current RSI of 26.144 indicates that the stock is oversold, but this does not guarantee a rebound. The forward P/E ratio is 0, reflecting a lack of profitability expectations, and the company has reported consistent net losses, with a net income of -1,654,000 USD in Q1 2026. The primary risk is the significant drop in stock price, which has decreased by 18.24% over the last five days, indicating ongoing bearish sentiment.